174 related articles for article (PubMed ID: 32525137)
1. Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
Ussowicz M
Drugs Today (Barc); 2020 Jun; 56(6):389-403. PubMed ID: 32525137
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
4. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Chichra A; Nayak L; Kothari R; Kalantri S; Bonda A; Gokarn A; Punatar S; Mirgh S; Jindal N; Bagal B; Kannan S; Mathew L; Khattry N
Int J Hematol; 2024 Jan; 119(1):71-79. PubMed ID: 37952243
[TBL] [Abstract][Full Text] [Related]
6. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.
Cseh A; Galimard JE; de la Fuente J; Isgro A; Zecca M; Garwer B; Biffi A; Aljurf M; Sundin M; Belendez C; Locatelli F; Balduzzi A; Lawson S; Sengeloev H; Ifversen M; Saccardi R; Wynn R; Lankester AC; Corbacioglu S; Peters C
Br J Haematol; 2024 Jan; 204(1):e1-e5. PubMed ID: 37795523
[TBL] [Abstract][Full Text] [Related]
7. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
8. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
10. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
12. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
Frietsch JJ; Miethke J; Linke P; Crodel CC; Schnetzke U; Scholl S; Hochhaus A; Hilgendorf I
Bone Marrow Transplant; 2022 Jul; 57(7):1164-1170. PubMed ID: 35538141
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Baronciani D; Rambaldi A; Iori AP; Di Bartolomeo P; Pilo F; Pettinau M; Depau C; Mico C; Santarone S; Angelucci E
Am J Hematol; 2008 Sep; 83(9):717-20. PubMed ID: 18626885
[TBL] [Abstract][Full Text] [Related]
14. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
16. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
[TBL] [Abstract][Full Text] [Related]
17. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
O'Hagan Henderson S; Frietsch JJ; Hilgendorf I; Hochhaus A; Köhne CH; Casper J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2599-2609. PubMed ID: 34674031
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J; Finke J; Labopin M; Craddock C; Protheroe R; Kottaridis P; Tholouli E; Byrne JL; Orchard K; Salmenniemi U; Hilgendorf I; Hunter H; Nicholson E; Bloor A; Snowden JA; Verbeek M; Clark A; Savani BN; Spyridonidis A; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Aug; 57(8):1269-1276. PubMed ID: 35568756
[TBL] [Abstract][Full Text] [Related]
19. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
20. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T; Volin L; Beelen DW; Trenschel R; Finke J; Schnitzler M; Holowiecki J; Giebel S; Markiewicz M; Uharek L; Blau IW; Kienast J; Stelljes M; Larsson K; Zander AR; Gramatzki M; Repp R; Einsele H; Stuhler G; Baumgart J; Mylius HA; Pichlmeier U; Freund M; Casper J
Haematologica; 2011 Sep; 96(9):1344-50. PubMed ID: 21659356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
